EUCTR2009-012989-30-ES进行中（未招募）1 期
Extensión multinacional, multicéntrica y de fase abierta con tratamiento activo del estudio MS-LAQ-301 (Allegro) para evaluar la seguridad a largo plazo, la tolerabilidad y el efecto sobre el curso de la enfermedad de la administración oral de laquinimod 0,6mg una vez al día en pacientes con esclerosis múltiple recurrente. -
Teva Pharmaceutical Industries Ltd0 个研究点目标入组 1,000 人开始时间: 2009年8月5日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subjects must have completed the Termination visit of MS-LAQ-301 (completion of all Termination visit activities) according to the MS-LAQ-301 protocol.
- •2.Women of child-bearing potential must practice an acceptable method of birth control during the study and up to 30 days after the last dose of the study drug.
- •3.Subjects must be willing and able to comply with the protocol requirements for the duration of the study.
- •4.Subjects must be able to comprehend, sign and date a written informed consent prior to entering the MS-LAQ-301E study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria:
- •1.Premature discontinuation from the MS-LAQ-301 study, for any reason.
- •2.Pregnancy [according to urine dipstick ?-HCG test performed at Baseline (Month 0E) visit] or breastfeeding.
- •3.Subjects with clinically significant or unstable medical or surgical condition detected or worsened during the MS-LAQ-301 study, which preclude safe participation and completion of the MS-LAQ-301E study. Acute exacerbation of MS will not exclude participation in the MS-LAQ-301E study.
- •4.Use of inhibitors of CYP3A4 within 2 weeks prior to baseline visit (V0E, Month 0E).
研究者
相似试验
进行中（未招募）
1 期
Extensión multinacional, multicéntrica y de fase abierta con tratamiento activo del estudio MS-LAQ-302 (Bravo) para evaluar la seguridad a largo plazo, la tolerabilidad y el efecto sobre el curso de la enfermedad de la administración oral de laquinimod 0,6mg una vez al día en pacientes con esclerosis múltiple recurrente -EUCTR2009-015815-42-ESTeva Pharmaceutical Industries Ltd1,245
进行中（未招募）
1 期
A Phase 3 Study of NTLA 2001 in participants with amyloidosis with cardiac muscle disease.Transthyretin Amyloidosis with CardiomyopathyMedDRA version: 20.0Level: SOCClassification code: 10007541Term: Cardiac disorders Class: 11CTIS2023-507220-23-00Intellia Therapeutics Inc.1,086
进行中（未招募）
1 期
Avalglucosidase Alfa Extension StudyPompe disease (acid alpha-glucosidase deficiency)MedDRA version: 20.0Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1Level: PTClassification code 10053185Term: Glycogen storage disease type IISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2013-003321-28-DKGenzyme Corporation21
进行中（未招募）
不适用
eoGAA Extension StudyPompe disease (acid alpha-glucosidase deficiency)MedDRA version: 18.0Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 100000004850EUCTR2013-003321-28-FRGenzyme Corporation18
进行中（未招募）
1 期
eoGAA Extension StudyPompe disease (acid alpha-glucosidase deficiency)MedDRA version: 20.0Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1Level: PTClassification code 10053185Term: Glycogen storage disease type IISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2013-003321-28-NLGenzyme Corporation21